Topics

Companies Related to "ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression directly" [Most Relevant Company Matches] RSS

21:16 EST 23rd January 2020 | BioPortfolio

Here are the most relevant search results for "ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression directly" found in our extensive corporate database of over 50,000 company records.

Showing "ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression directly" Companies 1–25 of 698

Relevant

Kite Pharma, Inc.

Kite Pharma, Inc. is a privately held development stage biotechnology company engaged in the design and development of cutting-edge immunotherapeutic products to treat different cancer indications. Kite's lead products include antigens associated with a wide variety of tumor types, and are initially being developed for the treatment of renal cell carcinoma...


Proteologics, Ltd.

Proteologics is an integrated biotechnology company that specializes in the ubiquitin system. The company's scientific advisory board is led by Drs. Avram Hershko and Aaron Ciechanover, who were recently awarded the 2004 Nobel Prize in chemistry for their discovery of the ubiquitin system. Proteologics combines world-class knowledge of the ubiquitin system with a unique platform that helps to disc...

Progenra Inc.

Progenra (www.progenra.com) aims to discover and develop novel medicines exploiting the ubiquitin proteasome system. Progenra has achieved leadership in ubiquitin proteasome system by utilizing the company’s UbiPro™ Drug Discovery Platform. Progenra has identified novel therapeutically relevant molecules for Parkinson’s disease by targeting ...


AVEO Pharmaceuticals Inc.

AVEO Pharmaceuticals is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. The Company’s lead candidate is tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, which AVEO is working to develop and commercialize in North America as a treatment for renal cell carcinoma (RC...

Progenra, Inc.

Founded in 2002, Progenra is committed to discovering and developing high value medicines based on ubiquitin and ubiquitin-like protein pathways. Its early stage product portfolio addresses major unmet medical needs in cancer, inflammation, metabolic diseases, pathogen infection, muscle wasting, and neurodegenerative disease. Progenra is utilizing its worl...

Ubiquigent Limited

Ubiquigent Limited (www.ubiquigent.com) is a specialist developer and supplier of high quality reagents, kits and drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. Ubiquigent's interests have a clear focus; namely the ubiquitin, ubiquitin-like and integrated signalling...

FIMECS, Inc.

FIMECS, Inc. is developing a new class of targeted protein degradation therapeutics for the treatment of cancer diseases. The company is focused on creating a new class of drugs based on protein degradation for ‘undruggable’ cancer targets – a term coined by industry to describe proteins that could not be targeted pharmacologically. By integrating ...

John HallLifeSensors Inc.

Founded in 1996, LifeSensors is a privately held biotechnology company located 35 miles west of Philadelphia. The main focus at LifeSensors is to develop enabling technologies to translate genome into proteome. The technology platform is based on an important family of proteins called ubiquitin or ubiquitin-like proteins (UBL), such as SUMO (Small Ubiquitin-like MOdifer). LifeSensors has filed pat...

Phoenix Pharmacologics Inc.,

Phoenix Pharmacologics Inc., with its principal headquarterslocated in, San Diego, California, is a privately-held emerging biopharmaceutical company that specializes in developing drugs to treat cancer and related disorders. Two of its protein drugs are in late stage clinical trials: ADI-PEG 20 for the treatment of hepatocellular carcinoma and metastatic melanoma,and Uricase-PEG 20 for the treatm...

Boston Biochem Incorporated

Boston Biochem is the world's leading producer of high quality specialized reagents for the Ubiquitin Proteasome Pathway. These products include enzymes, substrates, inhibitors, ubiquitin derivatives and assay kits. We also offer comprehensive custom services in the areas of protein purification, fermentation, protein expression optimization, protein conjugation and chemical synthesis.

Ubiquigent Ltd

Ubiquigent Limited is a specialist developer and supplier of Drug Discovery Services, high quality Research Tools and Chemistry to the life science research community worldwide. Ubiquigent’s scientific and business interests have a clear focus on the ubiquitin signalling system. The company has established its scientific and business credential...

Boston Biochem Inc.

Boston Biochem, Inc. is the world’s leading producer of Ubiquitin Proteasome Pathway products. Since our founding in 1997, it has been our mission to provide customers with innovative reagents for their research needs. All of our specialized reagents are developed, produced and characterized in-house with a commitment to quality and affordability. We provide personalized and knowledgeable custom...

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver....

Intracel

Intracel is a leading commercial-stage biotechnology company focused on the development of immune therapy to treat cancer. The company’s pipeline includes product development programs in active immunotherapy and fully human monoclonal antibodies. Intracel has completed clinical studies in Colon, Renal and Ovarian carcinoma, as well as Melanoma. Business StrategyRestructured company to focus o...

Nurix, Inc.

Nurix, Inc. is a leader in discovering and developing therapies that modulate the ubiquitin proteasome system (UPS). The UPS is a regulatory pathway that directs protein degradation, a function vital to the healthy life of a cell, and presents therapeutic opportunities in multiple disease areas, including oncology. Nurix’s state-of–the-art produc...

Progen Pharmaceuticals

Progen Pharmaceuticals Limited (NASDAQ:PGLA; ASX: PGL) is a globally focused biotechnology company committed to improving patient outcomes through discovery and development of small molecule-based cancer therapeutics. The company has an intimate understanding of the role of heparan sulfate, a complex sugar, in cancer disease processes and have developed a small-molecule drug development program i...

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2...

Peloton Therapeutics, Inc.

Peloton Therapeutics is a drug discovery and development company focused on advancing first-in-class small molecule therapies for cancer and other life-threatening diseases. Initial efforts are focused on hypoxia inducible factor-2α (HIF-2α), which has been implicated in the development and progression of several types of cancers. Peloton’s lead ...

YES

YES is a grassroots organization that provides cancer patients with support, resources, options, education and hope in their fight against liver tumors. It is made up of survivors who have undergone treatment for primary hepatocellular (liver) cancer or liver metastases (cancer that has spread to the liver) from other cancers. For more information ...

ChemomAb Ltd.

ChemomAb is a clinical stage biopharmaceutical company, specializing in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of fibrotic-inflammatory disorders including NASH, as well as the orphan indications Primary Sclerosing Cholangitis and Systemic Sclerosis. The antibodies are designed to treat patients with fibrotic and inflammatory diseas...

Orasi Medical, Inc.

Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and track the progression of neurological disorders using electrical brain activity. Orasi has developed a novel, quick, patient-friendly test of brain function that allows accurate assessment of disease progression and the effect of neurological tr...

ChemomAb

ChemomAb is a clinical stage biopharmaceutical company, specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of fibrotic-inflammatory disorders including NASH as well as orphan indications. The antibodies are designed to treat patients with fibrotic and inflammatory diseases through a novel ...

Cullgen Inc.

Cullgen is a drug discovery company leveraging ubiquitin-mediated, small molecule-induced protein degradation technology. The company's research programs focus on novel treatment for cancer, inflammatory, and autoimmune diseases. For more information, visit www.cullgen.com.

Probably Relevant

Plexium

Plexium is an emerging biotechnology company focused on the identification of E3 ligase modulating small molecules to treat cancer and neurodegenerative diseases. The company’s screening platform, named DELPhe for DNA-Encoded Library (DEL) phenotypic (Phe) screening, utilizes droplet and microwell confinement to miniaturize cell-based assays that yield high content readouts at very low cost ...

Bone Care International Incorporated

Bone Care is a leader in the discovery and development of improved vitamin D-hormone therapies for the treatment of secondary hyperparathyroidism and certain hyperproliferative diseases. D-hormones have a key role in the progression and management of secondary hyperparathyroidism in patient populations with kidney dysfunction, including kidney Dialysis, pre-dialysis, and certain osteoporosis pati...


More From BioPortfolio on "ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression directly"

Quick Search

Corporate Database Quicklinks